Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Accumulated Expenses (2017 - 2025)

Abeona Therapeutics (ABEO) has 13 years of Accumulated Expenses data on record, last reported at $6.9 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 32.21% year-over-year to $6.9 million; the TTM value through Sep 2025 reached $6.9 million, up 32.21%, while the annual FY2024 figure was $4.4 million, 19.09% up from the prior year.
  • Accumulated Expenses reached $6.9 million in Q3 2025 per ABEO's latest filing, up from $5.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $6.9 million in Q3 2025 and bottomed at $745000.0 in Q1 2022.
  • Average Accumulated Expenses over 5 years is $3.6 million, with a median of $3.7 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: crashed 74.02% in 2022, then soared 244.83% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $5.6 million in 2021, then crashed by 53.57% to $2.6 million in 2022, then skyrocketed by 42.23% to $3.7 million in 2023, then rose by 19.09% to $4.4 million in 2024, then surged by 56.83% to $6.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $6.9 million in Q3 2025, $5.5 million in Q2 2025, and $1.8 million in Q1 2025.